Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Consensus Rating of “Moderate Buy” from Brokerages

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $31.3333.

A number of analysts recently commented on GLUE shares. Wells Fargo & Company boosted their target price on Monte Rosa Therapeutics from $22.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, January 8th. Jefferies Financial Group restated a “buy” rating and set a $31.00 price objective on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Guggenheim increased their target price on Monte Rosa Therapeutics from $16.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Weiss Ratings restated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $37.00 price objective (up from $27.50) on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 14th.

Monte Rosa Therapeutics Stock Down 0.8%

Shares of NASDAQ GLUE opened at $17.80 on Monday. Monte Rosa Therapeutics has a 12-month low of $3.50 and a 12-month high of $25.77. The firm has a market cap of $1.16 billion, a PE ratio of 55.63 and a beta of 1.63. The company’s fifty day simple moving average is $19.99 and its 200 day simple moving average is $14.16.

Insider Transactions at Monte Rosa Therapeutics

In related news, insider Edmund Dunn sold 25,164 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $18.10, for a total transaction of $455,468.40. Following the completion of the sale, the insider owned 22,693 shares in the company, valued at approximately $410,743.30. This represents a 52.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Markus Warmuth sold 5,466 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $17.92, for a total value of $97,950.72. Following the completion of the sale, the chief executive officer directly owned 613,471 shares of the company’s stock, valued at $10,993,400.32. The trade was a 0.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 36,771 shares of company stock valued at $693,692 in the last quarter. Company insiders own 6.50% of the company’s stock.

Institutional Trading of Monte Rosa Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp increased its stake in shares of Monte Rosa Therapeutics by 148.9% during the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after purchasing an additional 1,260,707 shares during the last quarter. MPM Bioimpact LLC purchased a new position in Monte Rosa Therapeutics in the fourth quarter valued at approximately $18,399,000. AQR Capital Management LLC grew its holdings in Monte Rosa Therapeutics by 459.4% during the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after purchasing an additional 1,054,406 shares during the period. Braidwell LP purchased a new stake in Monte Rosa Therapeutics in the fourth quarter worth $14,870,000. Finally, Vestal Point Capital LP purchased a new stake in Monte Rosa Therapeutics in the third quarter worth $5,928,000. Hedge funds and other institutional investors own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.